Suvretta Capital Increases Stake in ArriVent BioPharma by 8.5%

Suvretta Capital Management LLC has increased its holdings in ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 8.5% during the third quarter of 2023, as reported in its latest filing with the U.S. Securities and Exchange Commission (SEC). The institutional investor now owns a total of 3,703,452 shares of ArriVent, following the acquisition of an additional 290,664 shares in the most recent quarter. This investment constitutes approximately 1.7% of Suvretta Capital’s portfolio, ranking it as the 17th largest position within the firm.

As of the most recent filing, Suvretta Capital’s stake in ArriVent BioPharma is valued at about $68,329,000, representing 8.97% of the company’s total shares. This notable investment has been complemented by other institutional activities. For example, Bessemer Group Inc. purchased a new stake in ArriVent during the third quarter, valued at $26,000. Similarly, Russell Investments Group Ltd. significantly increased its holdings by 9,747.6%, now possessing 2,068 shares valued at $38,000.

Another investor, BNP Paribas Financial Markets, expanded its position by 31.0% in the second quarter, owning 2,571 shares valued at $56,000. Tower Research Capital LLC also made substantial gains, growing its position by 571.6% and acquiring 6,669 shares valued at $145,000. In addition, Jane Street Group LLC entered the fray with a new stake worth approximately $189,000 in the first quarter. Currently, approximately 9.48% of ArriVent BioPharma’s stock is held by hedge funds and institutional investors.

Analyst Ratings and Market Performance

Recent analyst coverage has provided a mixed view on ArriVent BioPharma’s prospects. BTIG Research initiated coverage with a “buy” rating and set a target price of $42.00. Meanwhile, Truist Financial also rated the stock as a “buy,” with a price objective of $43.00. On the other hand, Weiss Ratings issued a “sell (d-)” rating on January 21, signaling caution regarding the stock’s future.

Overall, the consensus among analysts shows a polarized sentiment, with two analysts labeling the stock as a Strong Buy, eight as Buy, one as Hold, and one as Sell. According to data from MarketBeat, ArriVent BioPharma currently holds an average rating of “Moderate Buy,” with a mean target price of $40.78.

As of the last trading session, ArriVent BioPharma’s stock experienced a slight decline of 0.8%, opening at $23.90. The company boasts a market capitalization of $1.06 billion, a price-to-earnings ratio of -5.42, and a beta of 0.99. Over the past year, the stock has fluctuated between a low of $15.47 and a high of $27.22, with a 50-day moving average of $22.60 and a 200-day moving average of $21.09.

Company Overview

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on addressing unmet medical needs in oncology. The firm specializes in developing targeted therapies for conditions such as non-small cell lung cancer (NSCLC) and other solid tumors. Among its key projects is Furmonertinib, a third-generation tyrosine kinase inhibitor currently undergoing various clinical trials, including a phase 3 trial aimed at treating metastatic EGFR mutant NSCLC.

The company’s commitment to innovative cancer therapies positions it as a significant player in the biopharmaceutical landscape, particularly as it navigates the complexities of clinical development and market dynamics.

For those interested in tracking further developments related to ArriVent BioPharma, resources such as HoldingsChannel.com offer up-to-date information on institutional holdings and insider trading activities.